| Literature DB >> 27914035 |
Marcin Jabłoński1, Jolanta Kucharska Mazur2, Maciej Tarnowski3, Barbara Dołęgowska4, Daniel Pędziwiatr3, Ewa Kubiś3, Marta Budkowska4, Daria Sałata4, Justyna Pełka Wysiecka1, Arkadiusz Kazimierczak5, Artur Reginia1, Mariusz Z Ratajczak6, Jerzy Samochowiec1.
Abstract
In this paper we examined whether stem cells and factors responsible for their movement may serve as new biological markers of anxiety disorders. The study was carried out on a group of 30 patients diagnosed with panic disorder (examined before and after treatment), compared to 30 healthy individuals forming the control group. We examined the number of circulating HSCs (hematopoetic stem cells) (Lin-/CD45 +/CD34 +) and HSCs (Lin-/CD45 +/AC133 +), the number of circulating VSELs (very small embryonic-like stem cells) (Lin-/CD45-/CD34 +) and VSELs (Lin-/CD45-/AC133 +), as well as the concentration of complement components: C3a, C5a and C5b-9, SDF-1 (stromal derived factor) and S1P (sphingosine-1-phosphate). Significantly lower levels of HSCs (Lin-/CD45 +/AC133 +) have been demonstrated in the patient group compared to the control group both before and after treatment. The level of VSELs (Lin-/CD45-/CD133 +) was significantly lower in the patient group before treatment as compared to the patient group after treatment.The levels of factors responsible for stem cell movement were significantly lower in the patient group compared to the control group before and after treatment. It was concluded that the study of stem cells and factors associated with their movement can be useful in the diagnostics of panic disorder, as well as differentiating between psychotic and anxiety disorders.Entities:
Keywords: Complement components; Panic disorder; SDF-1; Sphingosine - 1 – phosphate; Stem cells; VSEL
Mesh:
Substances:
Year: 2017 PMID: 27914035 PMCID: PMC5380702 DOI: 10.1007/s12015-016-9700-6
Source DB: PubMed Journal: Stem Cell Rev Rep ISSN: 2629-3277 Impact factor: 5.739
Study groups: demographics and clinical features
| PG ( | CG ( | P | |
|---|---|---|---|
| Mean age (years) | 39,73 ± 9,4 | 34,13 ± 11.78 | 0,053 |
| Gender | Male - 7 (23,3 %) | Male - 10 (33,33 %) | 0,284 |
| Female – 23 (76,67 %) | Female - 20 (66,67 %) | ||
| Education | Elementary – 0(0 %) | Elementary – 1 (3,33 %) | 0,24 |
| Vocational school – 5 (17,86 %) | Vocational school – 1 (3,33 %) | ||
| Secondary −10 (35,71 %) | Secondary −13 (43,33 %) | ||
| Higher – 13 (46,43 %) | Higher – 15 (50,0 %) | ||
| Pregnancy – any complications | Yes – 6 (20 %) | Yes – 3 (10 %) | 0,27 |
| No – 24 (80 %) | No – 27 (90 %) | ||
| Natural childbirth | Yes – 26 (86,67 %) | Yes – 27 (90 %) | 0,68 |
| No – 4 (13.33 %) | No – 3 (10 %) | ||
| Divorce of parents | Yes – 8(26,67 %) | Yes – 3 (10 %) | 0,09 |
| No – 22 (73,33 %) | No - 27 (90 %) | ||
| Family history of psychotic disorders | Yes – 3 (10 %) | Yes – 6 (20 %) | 0,27 |
| No – 27 (90 %) | No – 24(80 %) | ||
| Smoking subjects | Yes – 15(55,56 %) | Yes – 11 (36,67 %) | 0,15 |
| No – 12 (44,44 %) | No – 19 (63,33 %) | ||
| BMI | 24,75 ± 4,8 | 24.61 ± 4.33 | 0,90 |
| Mean duration of anxiety (days) | 1564 ± 2297 | - | |
| Mean duration of treatment(days) | 24,47 ± 16,26 |
Mean MADRS and HAM-A scores in patient group before and after treatment
| Mean score before treatment | Mean score after treatment | p | |
|---|---|---|---|
| HAM-A | 22,2 ± 9,08 | 4,03 ± 5,57 | 0,00001 |
| MADRS | 8867 ± 5,82 | 1,9 ± 4413 | 0,00004 |
Comparison of stem cells concentrations and factors responsible for their movement in PG BT vs CG and comparison of the mean number of stem cells and factors responsible for their movement in PG AT vs CG.
| PG BT ( | CG ( | P | PG AT ( | CG ( | P | |
|---|---|---|---|---|---|---|
| VSELs (Lin−/CD45−/CD34+) [No.of cells/μl] | 0,155 ± 0,079 | 0,160 ± 0,103 | 0,82 | 0,158 ± 0,064 | 0,160 ± 0,103 | 0,93 |
| VSELs (Lin−/CD45−/CD133+) [No. of cells/μl] | 0,102 ± 0,048 | 0,116 ± 0,073 | 0,38 | 0,134 ± 0,074 | 0,116 ± 0,073 | 0,34 |
| HSCs (Lin−/CD45+/CD34+) [No. of cells/μl] | 1173 ± 0,522 | 1234 ± 0,692 | 0,7 | 1265 ± 0,62 | 1234 ± 0,692 | 0,85 |
| HSCs (Lin−/CD45+/AC133+) [No.of cells/μl] | 0,860 ± 0,43 | 1229 ± 0,736 | 0,02 | 0,897 ± 0,45 | 1229 ± 0,736 | 0,04 |
| C3a [ng/ml] | 469,56 ± 116,6 | 586,67 ± 136,2 | 0,00071 | 449,9 ± 86,13 | 586,67 ± 136,2 | 0,00002 |
| C5a [ng/ml] | 27 ± 13 | 54,11 ± 28,9 | 0,00001 | 26,98 ± 12,67 | 54,11 ± 28,9 | 0,00001 |
| C5b-9 [ng/ml] | 73,97 ± 77,29 | 235,95 ± 317,5 | 0,0087 | 61,43 ± 39,76 | 235,95 ± 317,5 | 0,0041 |
| SDF-1 [pg/ml] | 2101 ± 401 | 2828 ± 395 | 0,00001 | 2057,4 ± 422 | 2828 ± 395 | 0,00001 |
| S1P [μg/ml] | 2,05 ± 0,38 | 2,48 ± 0,13 | 0,00001 | 2,00 ± 0,32 | 2,48 ± 0,13 | 0,00001 |
Comparison of stem cell numbers and factors responsible for their movement in PG BT vs PG AT
| PG BT ( | PG AT ( | P | |
|---|---|---|---|
| VSEL (Lin−/CD45−/CD34+) [No.of cells/μl] | 0,155 ± 0,079 | 0,158 ± 0,064 | 0,797 |
| VSEL (Lin−/CD45/CD133+) [No.of cells/μl] | 0,102 ± 0,048 | 0,134 ± 0,074 | 0,0243 |
| HSCs (Lin−/CD45+/CD34+) [No.of cells/μl] | 1173 ± 0,522 | 1265 ± 0,62 | 0,245 |
| HSCs (Lin/CD45+/AC133+) [No.of cells/μl] | 0,860 ± 0,43 | 0,897 ± 0,45 | 0,416 |
| C3a [ng/ml] | 469,56 ± 116,6 | 449,9 ± 86,1 | 0,147 |
| C5a [ng/ml] | 27 ± 13 | 26,98 ± 12,6 | 1,0 |
| C5b-9 [ng/ml] | 73,97 ± 77,29 | 61,43 ± 39,7 | 0,36 |
| SDF-1 [pg/ml] | 2101 ± 401 | 2057,4 ± 422 | 0,496 |
| S1P [μg/ml] | 2,05 ± 0,38 | 2,00 ± 0,32 | 0,465 |
PG patient group, CG control group, BT before treatment, AT after treatment